![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
The FDA expanded the indication for Kisqali (ribociclib) (Novartis, novartis.com) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. The FDA also expanded the indication of Kisqali in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.
Text was dropped on page 16 in the Tools Department. The correct entry should read: “The FDA has approved Janssen Pharmaceutical Companies of Johnson & Johnson's (janssen.com) Darzalex® (daratumumab) in combination with Velcade® (bortezomib), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.” This correction has been made in the online version of the journal. The Editors apologize for the error.